相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure
Elias Jabbour et al.
BLOOD (2011)
Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia
Dragana Milojkovic et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history
E. Jabbour et al.
LEUKEMIA (2010)
BCR-ABL: a multi-faceted promoter of DNA mutation in chronic myelogeneous leukemia
B. A. Burke et al.
LEUKEMIA (2010)
Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations
Martin C. Mueller et al.
BLOOD (2009)
The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up
Ravin J. Garg et al.
BLOOD (2009)
Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet
Michele Baccarani et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Dasatinib in the Treatment of Chronic Myeloid Leukemia in Accelerated Phase After Imatinib Failure: The START A Trial
Jane F. Apperley et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Impact of Baseline BCR-ABL Mutations on Response to Nilotinib in Patients With Chronic Myeloid Leukemia in Chronic Phase
Timothy Hughes et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Advances in treatment of chronic myelogenous leukemia - new treatment options with tyrosine kinase inhibitors
Fabio P. S. Santos et al.
LEUKEMIA & LYMPHOMA (2009)
Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia
Constantine S. Tam et al.
BLOOD (2008)
BCR-ABL fusion transcript types and levels and their interaction with secondary genetic changes in determining the phenotype of Philadelphia chromosome-positive leukemias
Dan Jones et al.
BLOOD (2008)
BCR/ABL inhibits mismatch repair to protect from apoptosis and induce point mutations
Tomasz Stoklosa et al.
CANCER RESEARCH (2008)
Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression
Jamshid S. Khorashad et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
BCR/ABL promotes accumulation of chromosomal aberrations induced by oxidative and genotoxic stress
M. Koptyra et al.
LEUKEMIA (2008)
Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib
A. Hochhaus et al.
LEUKEMIA (2008)
Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase
J. Cortes et al.
LEUKEMIA (2008)
BCR/ABL, DNA damage and DNA repair: Implications for new treatment concepts
Tomasz Skorski
LEUKEMIA & LYMPHOMA (2008)
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia
Philipp le Coutre et al.
BLOOD (2008)
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance
Hagop M. Kantarjian et al.
BLOOD (2007)
Part I: Mechanisms of resistance to imatinib in chronic myeloid leukaemia
Jane F. Apperley
LANCET ONCOLOGY (2007)
Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency
Neil P. Shah et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia
Sergio A. Giralt et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells
Xiaoyan Jiang et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy
Andreas Hochhaus et al.
BLOOD (2007)
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
Brian J. Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate
E. Jabbour et al.
LEUKEMIA (2006)
Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet
Michele Baccarani et al.
BLOOD (2006)
Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure
Elias Jabbour et al.
BLOOD (2006)
ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: A study by the GIMEMA working party on chronic myeloid leukemia
S Soverini et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants
T O'Hare et al.
CANCER RESEARCH (2005)
Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate
J Cortes et al.
CLINICAL CANCER RESEARCH (2005)
Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis
S Branford et al.
BLOOD (2003)
Imatinib mesylate (ST1571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase
HM Kantarjian et al.
BLOOD (2002)
Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.
H Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro
SM Graham et al.
BLOOD (2002)
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the philadelphia chromosome.
BJ Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)